 Kindred Biosciences NASDAQ:KINs stock had its buy rating reiterated by analysts at HC Wainwright in a note issued to investors on Thursday, TipRanks reports. They currently have a 9.00 target price on the biopharmaceutical companys stock. HC Wainwrights target price would suggest a potential upside of 125.56 from the companys previous close. Other equities research ... 